Home
December 2008 January 2009 February 2009
Su Mo Tu We Th Fr Sa
Week 1 1 2 3
Week 2 4 5 6 7 8 9 10
Week 3 11 12 13 14 15 16 17
Week 4 18 19 20 21 22 23 24
Week 5 25 26 27 28 29 30 31

Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection - Abstract Show Comments PDF Print E-mail
  
Friday, 13 June 2008

Departments of Obstetrics and Gynecology and Urology, Loyola University Medical Center (LB), Maywood, Illinois.

We compared 200 U intradetrusor botulinum toxin A vs placebo in women with refractory idiopathic urge incontinence.

This institutional review board approved, multicenter registered trial randomized women with refractory urge incontinence, detrusor overactivity incontinence and 6 or greater urge incontinence episodes in 3 days to botulinum toxin A or placebo at a 2:1 ratio. Refractory was defined as inadequate symptom control after 2 or more attempts at pharmacotherapy and 1 or more other first line therapies for detrusor overactivity incontinence. The primary outcome measure was time to failure, as evidenced by a Patient Global Impression of Improvement score of 4 or greater at least 2 months after injection, or changes in treatment (initiation or increase) at any time after injection. Safety data, including increased post-void residual volume, defined as more than 200 ml irrespective of symptoms, was obtained at specified time points.

Approximately 60% of the women who received botulinum toxin A had a clinical response based on the Patient Global Impression of Improvement. The median duration of their responses was 373 days, significantly longer than the 62 days or less for placebo (p <0.0001). In the botulinum toxin A group increased post-void residual urine (12 of 28 women or 43%) and urinary tract infection in those with increased post-void residual urine (9 of 12 or 75%) exceeded expected ranges. Further injections were stopped after 43 patients were randomized, including 28 to botulinum toxin A and 15 to placebo.

Local injection of 200 U botulinum toxin A was an effective and durable treatment for refractory overactive bladder. However, a transient post-void residual urine increase was experienced in 43% of patients. Botulinum toxin A for idiopathic overactive bladder is still under investigation.

Written by
Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J.

Reference
J Urol. 2008 May 20. Epub ahead of print.

PubMed Abstract
PMID:18499184

UroToday.com Urinary Incontinence (UI) Section

 

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 1
PoorBest


 
Visitor Ratings:
No Affiliation:
4 (1 votes)